Stockscreener 앱 받기
13.25
2.16%
0.28
Contineum Therapeutics Inc 주식(CTNM)의 최신 뉴스
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Contineum Therapeutics (NASDAQ:CTNM) Stock Price Up 2.2%Here's What Happened - MarketBeat
Bank Watch: Can Contineum Therapeutics Inc stock outperform in a bear marketWeekly Trade Analysis & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Contineum Therapeutics CSO sells $56k in CTNM stock - Investing.com UK
Pre-planned stock sale by Contineum (CTNM) chief scientific officer - Stock Titan
Daniel Lorrain sells via 10b5-1; CTNM (NASDAQ: CTNM) Form 144 notice - Stock Titan
CTNM Technical Analysis & Stock Price Forecast - Intellectia AI
Contineum (CTNM) Q2 R&D Jumps 78% - aol.com
MACD Signal: Can Contineum Therapeutics Inc stock outperform in a bear market2026 Volume & Low Volatility Stock Recommendations - baoquankhu1.vn
Guidance Update: Is Contineum Therapeutics Inc currently under institutional pressure2026 Opening Moves & Stepwise Trade Signal Guides - baoquankhu1.vn
Sentiment Review: Is Contineum Therapeutics Inc currently under institutional pressureWeekly Investment Summary & Real-Time Market Sentiment Alerts - baoquankhu1.vn
We Think Contineum Therapeutics (NASDAQ:CTNM) Can Afford To Drive Business Growth - 富途牛牛
Companies Like Contineum Therapeutics (NASDAQ:CTNM) Are In A Position To Invest In Growth - simplywall.st
Retail Trends: What is the Moat Score of Contineum Therapeutics Inc2026 Pullbacks & Low Risk Entry Point Guides - baoquankhu1.vn
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Contineum Therapeutics (NASDAQ:CTNM) Trading 8.7% HigherStill a Buy? - MarketBeat
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Bond Watch: Will Corvus Pharmaceuticals Inc stock go up in YEAR2026 Levels & Daily Entry Point Trade Alerts - baoquankhu1.vn
Contineum Therapeutics, Inc.Common stock (NQ: CTNM - The Chronicle-Journal
Revenue Check: Is FKWL still a buy after recent gainsStock Surge & Detailed Earnings Play Alerts - baoquankhu1.vn
Contineum Therapeutics Highlights PIPE-791 IPF Trial, J&J-Backed PIPE-307 Catalysts at Leerink Conference - Defense World
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 13, 2026 - BioSpace
Contineum Therapeutics, Inc. $CTNM Shares Sold by Baker BROS. Advisors LP - MarketBeat
Baird Maintains Contineum Therapeutics (CTNM) Outperform Recommendation - MSN
Certain Options of Contineum Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-MAR-2026. - marketscreener.com
6,083,338 Class B common stock of Contineum Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-MAR-2026. - marketscreener.com
Contineum’s MS drug falls short in Phase II trial - MSN
Update Recap: How sensitive is Contineum Therapeutics Inc to inflationQuarterly Profit Review & Daily Chart Pattern Signals - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX), Contineum Therapeutics, Inc. Class A (CTNM) and Aktis Oncology, Inc. (AKTS) - The Globe and Mail
Contineum Therapeutics, Inc. (CTNM) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Contineum Therapeutics, Inc. Class A Common Stock share price - Mint
Can Contineum Therapeutics Inc. stock resist sector downturns2026 Institutional & Risk Adjusted Buy and Sell Alerts - Naître et grandir
Contineum Therapeutics (NASDAQ:CTNM) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
RBC Capital Remains a Buy on Contineum Therapeutics, Inc. Class A (CTNM) - The Globe and Mail
Contineum Therapeutics (NASDAQ:CTNM) Price Target Raised to $20.00 at Robert W. Baird - MarketBeat
Contineum Therapeutics Expands ATM Facility, Highlights Pipeline Progress - The Globe and Mail
Stifel reiterates Buy on Contineum stock, keeps $29 price target By Investing.com - Investing.com South Africa
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Developme - PharmiWeb.com
Stifel reiterates Buy on Contineum stock, keeps $29 price target - Investing.com India
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones - The National Law Review
Contineum Therapeutics (NASDAQ:CTNM) Posts Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Contineum reports Q4 EPS (49c), consensus (39c) - TipRanks
Contineum Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Contineum Therapeutics Q4 Earnings Summary & Key Takeaways - Benzinga
CTNM: Phase 2 IPF trial dosing started, $93M raised, and cash runway extends into mid-2029 - TradingView
Contineum Therapeutics (NASDAQ: CTNM) posts Q4 loss, adds $100,000,000 at-the-market stock capacity - Stock Titan
CTNM SEC FilingsContineum Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
According to the latest public documents from the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Contineum Therapeutics Inc. has launched a new stock offering plan. - Bitget
USD News Center - University of San Diego
Contineum Therapeutics Faces Downgrade Following Clinical Trial Setback () - aktiencheck.de
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference - Business Wire
CTNMContineum Therapeutics Latest Stock News & Market Updates - Stock Titan
2.69%
0.25%
자본화:
|
볼륨(24시간):